- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00379015
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving chemotherapy and a monoclonal antibody before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well giving epirubicin and cyclophosphamide followed by docetaxel and trastuzumab works in treating women with HER2-positive stage IIIB, stage IIIC, or stage IV primary breast cancer.
Przegląd badań
Status
Warunki
Szczegółowy opis
OBJECTIVES:
Primary
- Determine the pathological complete response in women with HER2-positive stage IIIB-IV breast cancer treated with neoadjuvant epirubicin hydrochloride and cyclophosphamide followed by docetaxel and trastuzumab (Herceptin®).
Secondary
- Determine the clinical response in patients treated with this regimen.
- Determine the recurrence-free survival of patients treated with this regimen.
- Determine the overall survival of patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive epirubicin hydrochloride and cyclophosphamide in weeks 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.
Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Niigata, Japonia, 951-8566
- Niigata Cancer Center Hospital
-
Tokyo, Japonia, 160-8582
- Keio University Hospital
-
Tokyo, Japonia, 173-8605
- Teikyo University School of Medicine
-
-
Ehime
-
Matsuyama-shi, Ehime, Japonia, 791-0288
- Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japonia, 811-1395
- National Kyushu Cancer Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
DISEASE CHARACTERISTICS:
Diagnosis of primary breast cancer
- Stage IIIB, IIIC, or IV disease
- No inflammatory disease
- HER2 over-expressing tumor as assessed by immunohistochemistry and/or fluorescent in situ hybridization
- Hormone receptor status known
PATIENT CHARACTERISTICS:
- Female
- Menopausal status not specified
- Performance status 0-1
- WBC ≤ 10,000/mm³
- Absolute neutrophil count ≥ 2,000/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.5 g/dL
- SGOT/SGPT ≤ 60 IU/L
- Bilirubin ≤ 1.5 mg/dL
- Creatinine ≤ 1.5 mg/dL
- LVEF ≥ 55%
- No signs of pneumonitis
PRIOR CONCURRENT THERAPY:
- No prior surgery except for biopsy
- No prior or concurrent chemotherapy and/or hormonal therapy
- No prior or concurrent biological therapy
- No prior or concurrent radiotherapy except postoperative radiotherapy
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: HER2 over-expressing primary breast cancer group
Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses. Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pathological complete response
Ramy czasowe: Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab
|
Pathological complete response is assessed in surgical resected specimens of primary tumor from patients who underwent a primary radical surgery in this study.
|
Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Clinical response
Ramy czasowe: From 7 days after the last adoministration of neosdjuvant therapy of Trastuzumab until surgery.
|
Clinical response is assessed as overall response in target lesion of primary tumor from 7 days after the last administration of neoadjuvant therapy of Trastuzumab until surgery.
|
From 7 days after the last adoministration of neosdjuvant therapy of Trastuzumab until surgery.
|
|
Pathological response of axillary lymph nodes
Ramy czasowe: Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab.
|
Pathological response of axillary lymph nodes is assessed in surgical specimens of primary tumor from patients who underwent a primary radical surgery in this study.
|
Whitin the first 7-28 days after the last administration of neoadjuvant therapy of trastuzumab.
|
|
Recurrence-free survival
Ramy czasowe: 8 years
|
Recurrence-free survival is defined as time from date of enrollment until date of recurrence or death from any cause, whichever comes first.
|
8 years
|
|
Overall survival
Ramy czasowe: 8 years
|
Overall survival is defined as time from date of enrollment until date of death from any cause.
|
8 years
|
|
Adverse event
Ramy czasowe: 70 months
|
Types and severities of adverse events from date of starting protocol treatment until 30 days after date of finishing the treatment are evaluated according to Japanese version of the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) by Translational Research Informatics Center.
|
70 months
|
Współpracownicy i badacze
Śledczy
- Krzesło do nauki: Tadashi Ikeda, MD, Teikyo University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby skórne
- Nowotwory
- Nowotwory według lokalizacji
- Choroby piersi
- Nowotwory piersi
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Inhibitory enzymów
- Środki przeciwreumatyczne
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Modulatory tubuliny
- Środki antymitotyczne
- Modulatory mitozy
- Środki przeciwnowotworowe, alkilujące
- Środki alkilujące
- Agoniści mieloablacyjni
- Inhibitory topoizomerazy II
- Inhibitory topoizomerazy
- Środki przeciwnowotworowe, immunologiczne
- Antybiotyki, Przeciwnowotworowe
- Docetaksel
- Cyklofosfamid
- Trastuzumab
- Epirubicyna
Inne numery identyfikacyjne badania
- CDR0000496448
- TUSM-BRI-BC04-01
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .